Anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death 1 (PD1)/Programmed death-ligand 1 (PD-L1) monoclonal antibodies have produced long-lasting anti-tumor immune responses that translate into clinical benefits for many cancer types [29]. Here, CTLA4 is linked to neoplasm.